Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 2, 2015, Pages 162-170

  Jiao, Qibin ^a   Ke, Qiang ^a   Li, Weiwei ^a   Jin, Meihua ^b   Luo, Yan ^a   Zhang, Linan ^a   Yang, Dong ^a   Zhang, Xingwei ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

C reactive protein; Cyclo oxygenase; Inflammation; No reflow phenomenon

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; C REACTIVE PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN SYNTHASE; STRESS ACTIVATED PROTEIN KINASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HEART MUSCLE PERFUSION; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MOLECULAR MECHANICS; NO REFLOW PHENOMENON; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ACUTE DISEASE; ANIMAL; DRUG EFFECTS; INFLAMMATION; METABOLISM; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ACUTE DISEASE; ANIMALS; C-REACTIVE PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INDOMETHACIN; INFLAMMATION; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84920868864     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12339     Document Type: Article

References (57)

1. Chan W, Stub D, Clark DJ et al. Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. Am. J. Cardiol. 2012; 109: 478-85.
2. Morishima I, Sone T, Okumura K et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J. Am. Coll. Cardiol. 2000; 36: 1202-9.
3. Reffelmann T, Kloner RA. The 'no-reflow' phenomenon: Basic science and clinical correlates. Heart 2002; 87: 162-8.
4. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105: 656-62.
5. Tomai F, Ribichini F, Ghini AS et al. Elevated c-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur. Heart J. 2005; 26: 2099-105.
6. Schindler TH, Nitzsche EU, Olschewski M et al. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation 2004; 110: 1069-75.
7. Lagrand WK, Niessen HW, Wolbink GJ et al. C-Reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.
8. Bagi Z, Erdei N, Toth A et al. Type 2 diabetic mice have increased arteriolar tone and blood pressure. Enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1610-6.
9. Guo Z, Su W, Allen S et al. Cox-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc. Res. 2005; 67: 723-35.
10. Heymes C, Habib A, Yang D et al. Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br. J. Pharmacol. 2000; 131: 804-10.
11. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344-8.
12. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br. J. Pharmacol. 2005; 144: 449-58.
13. Alvarez Y, Briones AM, Balfagon G, Alonso MJ, Salaices M. Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses. J. Hypertens. 2005; 23: 767-77.
14. Bratz IN, Kanagy NL. Nitric oxide synthase-inhibition hypertension is associated with altered endothelial cyclooxygenase function. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H2394-401.
15. Grim TW, Ghosh S, Hsu KL, Cravatt BF, Kinsey SG, Lichtman AH. Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol. Biochem. Behav. 2014; 124C: 405-11.
16. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem. 1999; 274: 5038-46.
17. Celik T, Iyisoy A, Kursaklioglu H et al. The impact of admission c-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron. Artery Dis. 2005; 16: 293-9.
18. Zhu N, Liu B, Luo W et al. Vasoconstrictor role of cyclooxygenase-1-mediated prostacyclin synthesis in non-insulin-dependent diabetic mice induced by high-fat diet and streptozotocin. Am. J. Physiol. Heart Circ. Physiol. 2014; 307: H319-27.
19. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by c-reactive protein. Cardiovasc. Res. 2003; 58: 186-95.
20. Gibson CM, Schomig A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096-105.
21. Mazzone A, De Servi S, Ricevuti G et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-63.
22. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-Reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-9.
23. Theroux P, Armstrong PW, Mahaffey KW et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the comma trial. Eur. Heart J. 2005; 26: 1964-70.
24. Tomoda H, Aoki N. Prognostic value of c-reactive protein levels within six hours after the onset of acute myocardial infarction. Am. Heart J. 2000; 140: 324-8.
25. Yip HK, Hang CL, Fang CY et al. Level of high-sensitivity c-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005; 127: 803-8.
26. Miller JD, Peotta VA, Chu Y et al. Mnsod protects against COX1-mediated endothelial dysfunction in chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2010; 298: H1600-7.
27. Kuwano T, Nakao S, Yamamoto H et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 2004; 18: 300-10.
28. Samad TA, Moore KA, Sapirstein A et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410: 471-5.
29. Rodrigo R, Libuy M, Feliu F, Hasson D. Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage. Dis. Markers 2013; 35: 773-90.
30. Yang D, Feletou M, Boulanger CM et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br. J. Pharmacol. 2002; 136: 104-10.
31. Yang D, Feletou M, Levens N, Zhang JN, Vanhoutte PM. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 2003; 41: 143-8.
32. St-Louis I, Singh M, Brasseur K, Leblanc V, Parent S, Asselin E. Expression of Cox-1 and Cox-2 in the endometrium of cyclic, pregnant and in a model of pseudopregnant rats and their regulation by sex steroids. Reprod. Biol. Endocrinol. 2010; 8: 103.
33. Amico C, Yakimov M, Catania MV, Giuffrida R, Pistone M, Enea V. Differential expression of cyclooxygenase-1 and cyclooxygenase-2 in the cornea during wound healing. Tissue Cell 2004; 36: 1-12.
34. Botto N, Sbrana S, Trianni G et al. An increased platelet-leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: A pathogenic role for 'no-reflow' phenomenon? Int. J. Cardiol. 2007; 117: 123-30.
35. Wu KK. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot. Essent. Fatty Acids 2005; 72: 89-93.
36. Egan KM, Lawson JA, Fries S et al. Cox-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306: 1954-7.
37. Yu Y, Ricciotti E, Scalia R et al. Vascular Cox-2 modulates blood pressure and thrombosis in mice. Sci. Transl. Med. 2012; 4: 132ra154.
38. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8.
39. Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Feletou M. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: The Janus face of prostacyclin. Br. J. Pharmacol. 2005; 146: 834-45.
40. Liu B, Luo W, Zhang Y et al. Concomitant activation of functionally opposing prostacyclin and thromboxane prostanoid receptors by cyclo-oxygenase-1-mediated prostacyclin synthesis in mouse arteries. Exp. Physiol. 2012; 97: 895-904.
41. Camitta MG, Gabel SA, Chulada P et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001; 104: 2453-8.
42. Pepys MB. C-Reactive protein fifty years on. Lancet 1981; 1: 653-7.
43. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999; 340: 448-54.
44. Ridker PM. Clinical application of c-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
45. Burke AP, Tracy RP, Kolodgie F et al. Elevated c-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation 2002; 105: 2019-23.
46. Ridker PM, Buring JE, Cook NR, Rifai N. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-7.
47. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J. 2002; 23: 831-4.
48. Verma S, Wang CH, Weisel RD et al. Hyperglycemia potentiates the proatherogenic effects of c-reactive protein: Reversal with rosiglitazone. J. Mol. Cell. Cardiol. 2003; 35: 417-9.
49. Bisoendial RJ, Kastelein JJ, Levels JH et al. Activation of inflammation and coagulation after infusion of c-reactive protein in humans. Circ. Res. 2005; 96: 714-6.
50. + monocyte-derived dendritic cell differentiation, maturation and function. Eur. J. Immunol. 2006; 36: 2993-3006.
51. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J. Am. Coll. Cardiol. 2000; 36: 959-69.
52. Gibson CM, Cannon CP, Murphy SA et al. Relationship of timi myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-30.
53. Zhao XM, Sun S, Liu XH. Experimental model of myocardial ischemia/reperfusion in rat established by ligating coronary artery with capsule. J. Chin. Microcirc. 2007; 11: 206-8.
54. Li XD, Yang YJ, Geng YJ et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am. J. Physiol. Heart Circ. Physiol. 2010; 299: H1255-61.
55. 2+-handling proteins and endoplasmic reticulum stress in mice. Clin. Exp. Pharmacol. Physiol. 2014; 41: 589-99.
56. Jiao Q, Takeshima H, Ishikawa Y, Minamisawa S. Sarcalumenin plays a critical role in age-related cardiac dysfunction due to decreases in Serca2a expression and activity. Cell Calcium 2012; 51: 31-9.
57. Jiao Q, Bai Y, Akaike T, Takeshima H, Ishikawa Y, Minamisawa S. Sarcalumenin is essential for maintaining cardiac function during endurance exercise training. Am. J. Physiol. Heart Circ. Physiol. 2009; 297: H576-82.